These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 32061290)

  • 1. Protective strategies to prevent trastuzumab-induced cardiotoxicity - Authors' reply.
    Earl HM; Hiller L; Plummer C; Miles D; Wardley AM; Cameron DA; Dunn JA
    Lancet; 2020 Feb; 395(10223):492-493. PubMed ID: 32061290
    [No Abstract]   [Full Text] [Related]  

  • 2. Protective strategies to prevent trastuzumab-induced cardiotoxicity.
    Guo S; Tse G; Liu T
    Lancet; 2020 Feb; 395(10223):491-492. PubMed ID: 32061289
    [No Abstract]   [Full Text] [Related]  

  • 3. Pertuzumab-induced cardiotoxicity: safety compared with trastuzumab.
    Sendur MA; Aksoy S; Altundag K
    Future Oncol; 2015; 11(1):13-5. PubMed ID: 25572781
    [No Abstract]   [Full Text] [Related]  

  • 4. Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies.
    Rayson D; Richel D; Chia S; Jackisch C; van der Vegt S; Suter T
    Ann Oncol; 2008 Sep; 19(9):1530-9. PubMed ID: 18480068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. More predictive markers were identified for trastuzumab-induced cardiotoxicity.
    Altundag K
    Med Oncol; 2017 Dec; 35(1):8. PubMed ID: 29214356
    [No Abstract]   [Full Text] [Related]  

  • 6. Trastuzumab interruption and treatment-induced cardiotoxicity in early HER2-positive breast cancer.
    Yu AF; Yadav NU; Lung BY; Eaton AA; Thaler HT; Hudis CA; Dang CT; Steingart RM
    Breast Cancer Res Treat; 2015 Jan; 149(2):489-95. PubMed ID: 25552363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiotoxicity of ErbB2-targeted therapies and its impact on drug development, a spotlight on trastuzumab.
    Dokmanovic M; King KE; Mohan N; Endo Y; Wu WJ
    Expert Opin Drug Metab Toxicol; 2017 Jul; 13(7):755-766. PubMed ID: 28571477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term Cardiopulmonary Consequences of Treatment-Induced Cardiotoxicity in Survivors of ERBB2-Positive Breast Cancer.
    Yu AF; Flynn JR; Moskowitz CS; Scott JM; Oeffinger KC; Dang CT; Liu JE; Jones LW; Steingart RM
    JAMA Cardiol; 2020 Mar; 5(3):309-317. PubMed ID: 31939997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concerns about cardiotoxicity in the HERA trial - Authors' reply.
    Cameron DA; Gelber RD; Procter M; Suter T
    Lancet; 2017 Dec; 390(10114):2767-2768. PubMed ID: 29303722
    [No Abstract]   [Full Text] [Related]  

  • 10. Cardiotoxicity and Cardiac Monitoring During Adjuvant Trastuzumab in Daily Dutch Practice: A Study of the Southeast Netherlands Breast Cancer Consortium.
    Seferina SC; de Boer M; Derksen MW; van den Berkmortel F; van Kampen RJ; van de Wouw AJ; Joore M; Peer PG; Voogd AC; Tjan-Heijnen VC
    Oncologist; 2016 May; 21(5):555-62. PubMed ID: 27009939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study.
    Jacquinot Q; Meneveau N; Chatot M; Bonnetain F; Degano B; Bouhaddi M; Dumoulin G; Vernerey D; Pivot X; Mougin F
    BMC Cancer; 2017 Jun; 17(1):425. PubMed ID: 28629338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous Trastuzumab Therapy in Breast Cancer Patients With Asymptomatic Left Ventricular Dysfunction.
    Yu AF; Yadav NU; Eaton AA; Lung BY; Thaler HT; Liu JE; Hudis CA; Dang CT; Steingart RM
    Oncologist; 2015 Oct; 20(10):1105-10. PubMed ID: 26240135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab-Related Cardiotoxicity and Cardiac Care in Patients With HER2 Positive Metastatic Breast Cancer.
    Calvillo-Argüelles O; Abdel-Qadir H; Suntheralingam S; Michalowska M; Amir E; Thavendiranathan P
    Am J Cardiol; 2020 Apr; 125(8):1270-1275. PubMed ID: 32087998
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and identification of risk factors for trastuzumab-induced cardiotoxicity in breast cancer patients: an audit of a single "real-world" setting.
    Tang GH; Acuna SA; Sevick L; Yan AT; Brezden-Masley C
    Med Oncol; 2017 Sep; 34(9):154. PubMed ID: 28779423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Prospective Study About Trastuzumab-induced Cardiotoxicity in HER2-positive Breast Cancer.
    Ben Kridis W; Sghaier S; Charfeddine S; Toumi N; Daoud J; Kammoun S; Khanfir A
    Am J Clin Oncol; 2020 Jul; 43(7):510-516. PubMed ID: 32304433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors predicting trastuzumab-related cardiotoxicity in a real-world population of women with HER2+ breast cancer.
    Naumann D; Rusius V; Margiotta C; Nevill A; Carmichael A; Rea D; Sintler M
    Anticancer Res; 2013 Apr; 33(4):1717-20. PubMed ID: 23564821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors for developing cardiotoxicity of trastuzumab in breast cancer patients: An observational single-centre study.
    Gunaldi M; Duman BB; Afsar CU; Paydas S; Erkisi M; Kara IO; Sahin B
    J Oncol Pharm Pract; 2016 Apr; 22(2):242-7. PubMed ID: 25567518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiotoxicity Assessment After Different Adjuvant Hypofractionated Radiotherapy Concurrently Associated with Trastuzumab in Early Breast Cancer.
    Bonzano E; Guenzi M; Corvò R
    In Vivo; 2018; 32(4):879-882. PubMed ID: 29936473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Observational study of trastuzumab-related cardiotoxicity in early and metastatic breast cancer.
    Grazziotin LR; Picon PD
    J Oncol Pharm Pract; 2017 Jun; 23(4):264-272. PubMed ID: 26983449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Left atrial volume in patients with HER2-positive breast cancer: One step further to predict trastuzumab-related cardiotoxicity.
    Bergamini C; Dolci G; Rossi A; Torelli F; Ghiselli L; Trevisani L; Vinco G; Truong S; La Russa F; Golia G; Molino A; Benfari G; Ribichini FL
    Clin Cardiol; 2018 Mar; 41(3):349-353. PubMed ID: 29569424
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.